Bill > HRes484

This resolution expresses support for recognizing the first week of June as "Hidradenitis Suppurativa Awareness Week" and aims to raise awareness about Hidradenitis Suppurativa (HS), a chronic inflammatory skin disease that affects approximately 3.3 million people in the United States. The resolution highlights the significant challenges faced by individuals with HS, including painful nodules, extensive scarring, and profound psychological distress, and notes that 75 percent of patients are misdiagnosed or diagnosed after age 25. The resolution calls for increasing public and professional awareness about HS, promoting timely and accurate diagnosis, supporting biomedical research to better understand the disease, accelerating treatment development, and advancing policies that address care disparities. The document emphasizes the serious nature of HS, pointing out that it is associated with one of the highest suicide rates among dermatological diseases and can significantly impact patients' ability to work and maintain relationships, while also noting that as of June 1, 2025, only three biologic therapies are FDA-approved for HS treatment.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-resolution/484/all-info